



**BlueCross
BlueShield**

Federal Employee Program.

Blue Cross Blue Shield Association
750 9th St NW, Suite 900
Washington, D.C. 20001
1-800-624-5060
Fax 1-877-378-4727

5.45.015

Section:	Prescription Drugs	Effective Date:	July 1, 2026
Subsection:	Respiratory Agents	Original Policy Date:	January 28, 2022
Subject:	Tezspire	Page:	1 of 7

Last Review Date: June 11, 2026

Tezspire

Description

Tezspire (tezepelumab-ekko)

Background

Tezspire (tezepelumab-ekko) is a thymic stromal lymphopoietin (TSLP) blocker, human monoclonal antibody IgG2 λ that binds to human TSLP and blocks its interaction with the heterodimeric TSLP receptor. TSLP is a cytokine mainly derived from epithelial cells and occupies an upstream position in inflammatory cascades. Blocking TSLP reduces biomarkers and cytokines associated with inflammation. Airway and mucosal inflammation are important components in the pathogenesis of asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) (1).

Regulatory Status

FDA-approved indications: Tezspire is a thymic stromal lymphopoietin (TSLP) blocker, human monoclonal antibody (IgG2 λ), indicated: (1)

- For the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
- For the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP),

Limitations of Use: (1)

- Not for relief of acute bronchospasm or status asthmaticus.

Section:	Prescription Drugs	Effective Date:	July 1, 2026
Subsection:	Respiratory Agents	Original Policy Date:	January 28, 2022
Subject:	Tezspire	Page:	2 of 7

Tezspire contains warnings regarding the following: hypersensitivity reactions; acute asthma symptoms or deteriorating disease; risk associated with abrupt reduction of corticosteroid dosage; parasitic (helminth) infection; and live attenuated vaccines (1).

FEP adherence is defined as $\geq 50\%$ utilization within the last 180 days.

The safety and effectiveness of Tezspire in pediatric patients less than 12 years of age have not been established (1).

Related policies

Cinqair, Dupixent, IL-5 Antagonist, Xolair

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Tezspire may be considered **medically necessary** if the conditions indicated below are met.

Tezspire may be considered **investigational** for all other indications.

Prior-Approval Requirements

Age 12 years of age or older

Diagnosis

Patient must have the following with provided documentation (e.g., medical records, laboratory reports):

1. Severe asthma
 - a. Inadequate control of asthma symptoms after a minimum of 3 months of compliant use with greater than or equal to 50% adherence with **ONE** of the following within the past 6 months:
 - i. Inhaled corticosteroids & long acting beta₂ agonist
 - ii. Inhaled corticosteroids & long acting muscarinic antagonist
 - b. Used as add-on maintenance treatment and patient will be receiving **ALL** of the following:
 - i. Medium or high-dose inhaled corticosteroid

Section:	Prescription Drugs	Effective Date:	July 1, 2026
Subsection:	Respiratory Agents	Original Policy Date:	January 28, 2022
Subject:	Tezspire	Page:	3 of 7

- ii. An additional controller medication (e.g., long acting beta₂ agonist, leukotriene modifier)
 - c. Documentation of baseline serum IgE level and eosinophil count
 - d. **NOT** used for the relief of acute bronchospasm or status asthmaticus
 - e. **NO** dual therapy with another monoclonal antibody for the treatment of asthma or COPD (see Appendix 1)
 - f. **NOT** given concurrently with live vaccines
 - g. Patient **MUST** have tried the preferred product(s) (see Appendix 3) unless the patient has a valid medical exception (e.g., inadequate treatment response, intolerance, contraindication)
- 2. Chronic rhinosinusitis with nasal polyps (CRSwNP)
 - a. Inadequate treatment response, intolerance or contraindication to a 3-month trial of **TWO** nasal corticosteroid sprays (i.e., mometasone, fluticasone, budesonide, or triamcinolone)
 - b. Used as add-on maintenance treatment
 - c. **NO** dual therapy with another monoclonal antibody for the treatment of CRSwNP (see Appendix 2)
 - d. **NOT** given concurrently with live vaccines
 - e. 18 years of age and older **ONLY**: Patient **MUST** have tried the preferred product(s) (see Appendix 3) unless the patient has a valid medical exception (e.g., inadequate treatment response, intolerance, contraindication)

All approved requests are subject to review by a clinical specialist for final validation and coverage determination once all required documentation has been received. Current utilization, including samples, does not guarantee approval of coverage.

Prior – Approval *Renewal* Requirements

Age 12 years of age or older

Diagnosis

Patient must have the following with provided documentation (e.g., medical records, laboratory reports):

1. Asthma

Section:	Prescription Drugs	Effective Date:	July 1, 2026
Subsection:	Respiratory Agents	Original Policy Date:	January 28, 2022
Subject:	Tezspire	Page:	4 of 7

- a. Decreased exacerbations **OR** improvement in symptoms
 - b. Decreased utilization of rescue medications
 - c. Patient has been compliant on Tezspire therapy
 - d. Used as add-on maintenance treatment
 - e. **NOT** used for the relief of acute bronchospasm or status asthmaticus
 - f. **NO** dual therapy with another monoclonal antibody for the treatment of asthma or COPD (see Appendix 1)
 - g. **NOT** given concurrently with live vaccines
 - h. Patient **MUST** have tried the preferred product(s) (see Appendix 3) unless the patient has a valid medical exception (e.g., inadequate treatment response, intolerance, contraindication)
2. Chronic rhinosinusitis with nasal polyps (CRSwNP)
- a. Improvement in sino-nasal symptoms
 - b. Used as add-on maintenance treatment
 - c. Patient has been compliant on Tezspire therapy
 - d. **NO** dual therapy with another monoclonal antibody for the treatment of asthma or COPD (see Appendix 1)
 - e. **NOT** given concurrently with live vaccines
 - f. 18 years of age and older **ONLY**: Patient **MUST** have tried the preferred product(s) (see Appendix 3) unless the patient has a valid medical exception (e.g., inadequate treatment response, intolerance, contraindication)

All approved requests are subject to review by a clinical specialist for final validation and coverage determination once all required documentation has been received. Current utilization, including samples, does not guarantee approval of coverage.

Policy Guidelines

Pre - PA Allowance

None

Prior - Approval Limits

Quantity

Strength / Dosage Form	Quantity
210 mg / 1.91 mL single-dose vial	3 units per 84 days

Section:	Prescription Drugs	Effective Date:	July 1, 2026
Subsection:	Respiratory Agents	Original Policy Date:	January 28, 2022
Subject:	Tezspire	Page:	5 of 7

210 mg / 1.91 mL single-dose pre-filled syringe	
210 mg / 1.91 mL single-dose pre-filled pen	

Duration 12 months

Prior – Approval *Renewal* Limits

Same as above

Rationale

Summary

Tezspire (tezepelumab-ekko) is a TSLP blocker and human monoclonal antibody that is used for the add-on maintenance treatment of patients 12 years and older with severe asthma or CRSwNP. Tezspire is not used for the relief of acute bronchospasm or status asthmaticus. It is also recommended to avoid the use of live attenuated vaccines with Tezspire. The safety and effectiveness of Tezspire in pediatric patients less than 12 years of age have not been established (1).

Prior authorization is required to ensure the safe, clinically appropriate, and cost-effective use of Tezspire while maintaining optimal therapeutic outcomes.

References

1. Tezspire [package insert]. Thousand Oaks, CA: AstraZeneca AB, Inc.; October 2025.
2. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2021. Available from www.ginasthma.org.

Policy History

Date	Action
January 2022	Addition to PA
March 2022	Annual review
April 2022	Per FEP, added initiation requirement that patient must be using as add-on maintenance treatment and will be using with a medium or high-dose corticosteroid and an additional controller medication and added renewal requirement that patient must be using as add-on maintenance treatment.

Section:	Prescription Drugs	Effective Date:	July 1, 2026
Subsection:	Respiratory Agents	Original Policy Date:	January 28, 2022
Subject:	Tezspire	Page:	6 of 7

June 2022	Annual review
September 2022	Annual review
February 2023	Per PI update, added new dosage form pre-filled pen
June 2023	Annual review
December 2023	Annual review. Per SME, changed renewal requirement to decreased exacerbations or improvement in symptoms
December 2024	Annual editorial review. Added Appendix 1
December 2025	Annual editorial review. Per PI update, added indication of CRSwNP. Added t/f 2 preferred options
June 2026	Annual review

Keywords

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on June 11, 2026 and is effective on July 1, 2026.

Section:	Prescription Drugs	Effective Date:	July 1, 2026
Subsection:	Respiratory Agents	Original Policy Date:	January 28, 2022
Subject:	Tezspire	Page:	7 of 7

Appendix 1 - List of Monoclonal Antibodies for Asthma or COPD

Generic Name	Brand Name
benralizumab	Fasenra
dupilumab	Dupixent
mepolizumab	Nucala
omalizumab	Xolair
reslizumab	Cinqair
tezepelumab-ekko	Tezspire

Appendix 2 - List of Monoclonal Antibodies for CRSwNP

Generic Name	Brand Name
dupilumab	Dupixent
mepolizumab	Nucala
omalizumab	Xolair
tezepelumab-ekko	Tezspire

Appendix 3 - List of Preferred Products

List of preferred products:

https://info.caremark.com/content/dam/enterprise/caremark/microsites/dig/pdfs/pa-fep/fep-misc/FEP_IndicationMedChx.pdf

Refer to formulary documents for confirmation of coverage:

<https://www.fepblue.org/pharmacy/prescriptions#drug-lists>